<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123966">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488708</url>
  </required_header>
  <id_info>
    <org_study_id>13811</org_study_id>
    <secondary_id>H9B-MC-BCDX</secondary_id>
    <nct_id>NCT01488708</nct_id>
  </id_info>
  <brief_title>On Open-Label Study in Participants With Systemic Lupus Erythematosus</brief_title>
  <acronym>Illuminate-X</acronym>
  <official_title>A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399
      in eligible SLE participants who have completed the core studies (NCT01196091)
      (NCT01205438).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>Baseline through 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a systemic lupus erythematosus (SLE) responder index (SRI) response</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a reduction in steroid dose</measure>
    <time_frame>Baseline through 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SLE Disease Activity Index</measure>
    <time_frame>Baseline, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new severe SLE flares</measure>
    <time_frame>Baseline through 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with improvement in Lupus Quality of Life</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-double-stranded deoxyribonucleic acid level</measure>
    <time_frame>Baseline, 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1518</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Connective Tissue Disease</condition>
  <condition>Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>LY 2127399 Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2127399 Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399</intervention_name>
    <description>120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies are not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.</description>
    <arm_group_label>LY 2127399 Q2W</arm_group_label>
    <arm_group_label>LY2127399 Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
    <arm_group_label>LY 2127399 Q2W</arm_group_label>
    <arm_group_label>LY2127399 Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)

          -  Given written informed consent

          -  Test negative for pregnancy at the time of enrollment

          -  Agree to use a reliable method of birth control

        Exclusion Criteria:

          -  Unwilling to comply with study procedures

          -  Any condition that renders the participants unable to understand the nature and scope
             and possible consequences of the study

          -  Any condition that in the opinion of the investigator poses an unacceptable risk to
             the participants if study drug would be administered
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY(1-877-285-4559 or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT-5 hours, EST</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 10, 2016</lastchanged_date>
  <firstreceived_date>December 6, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>March 10, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>SLE</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Immune System Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
